1. Home
  2. ENTA vs FFA Comparison

ENTA vs FFA Comparison

Compare ENTA & FFA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Enanta Pharmaceuticals Inc.

ENTA

Enanta Pharmaceuticals Inc.

HOLD

Current Price

$12.85

Market Cap

486.3M

Sector

Health Care

ML Signal

HOLD

Logo First Trust Enhanced Equity Income Fund

FFA

First Trust Enhanced Equity Income Fund

HOLD

Current Price

$22.03

Market Cap

429.4M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
ENTA
FFA
Founded
1995
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
486.3M
429.4M
IPO Year
2013
N/A

Fundamental Metrics

Financial Performance
Metric
ENTA
FFA
Price
$12.85
$22.03
Analyst Decision
Strong Buy
Analyst Count
5
0
Target Price
$20.40
N/A
AVG Volume (30 Days)
283.1K
26.1K
Earning Date
02-09-2026
01-01-0001
Dividend Yield
N/A
6.72%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$65,324,000.00
N/A
Revenue This Year
$0.99
N/A
Revenue Next Year
$0.19
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.09
$15.84
52 Week High
$17.15
$19.30

Technical Indicators

Market Signals
Indicator
ENTA
FFA
Relative Strength Index (RSI) 41.35 52.11
Support Level $12.09 $21.55
Resistance Level $13.98 $22.13
Average True Range (ATR) 0.73 0.17
MACD -0.22 -0.03
Stochastic Oscillator 19.01 55.17

Price Performance

Historical Comparison
ENTA
FFA

About ENTA Enanta Pharmaceuticals Inc.

Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.

About FFA First Trust Enhanced Equity Income Fund

First Trust Enhanced Equity Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide high level of current income and gains and, to a lesser extent, capital appreciation. The Fund pursues its investment objective by investing in a diversified portfolio of equity securities.

Share on Social Networks: